PLAP for Treating Dyslipidemia
Several major trials (listed in the Table below) have established without doubt that in
patients with high triglyceride (TG) levels, statins less effectively reduce the risk of
cardiovascular (CV) disease. The solution is to use a combination treatment composed
of statin, to lower LDL-cholesterol, and another drug to efficiently reduce triglyceride.
Zoltan Laboratories has discovered that combined treatment of obese type 2
diabetic mice with statin and PLAP results in simultaneous normalization of serum
levels of LDL-cholesterol, triglyceride, and free fatty acids, while statin alone has a
major effect only on LDL-cholesterol. The future developer of this project for clinical
use is expected to demonstrate that the statin-PLAP composition will further reduce
the risk of cardiovascular diseases. In addition, preclinical trials indicate that PLAP
will prevent major side effects of statins such as reduction of muscle proteins and
increase of blood glucose level.